Completed PHASE2 INTERVENTIONAL 2-arm NCT00880893

Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions Dengue Diseases Dengue Fever Dengue Hemorrhagic Fever Dengue Virus

Interventions CYD Dengue vaccine NaCl + influenza virus or hepatitis A vaccine

Updated 7 times since 2017 Last updated: Mar 10, 2022 Started: Apr 7, 2009 Primary completion: Oct 31, 2014 Completion: Oct 14, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Dengue Diseases and Dengue Fever and is currently completed. Sanofi Pasteur, a Sanofi Company leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Aug 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi Pasteur, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore